title: Autosomal dominant polycystic kidney disease: new insights into treatment.
abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the world's most common inherited kidney disease. An increasing number of animal and human studies have enhanced our understanding of the molecular and cellular pathology of ADPKD. New treatment options are being tested in clinical trials in spite of the failure of mammalian target of rapamycin inhibitor therapy. The main and most effective therapy remains control of hypertension by renin-angiotensin-aldosterone system (RAAS) blockade. This review focuses only on promising therapies, including dual inhibition of RAAS, vasopressin receptor antagonists, increased fluid intake, and blockade of certain receptors of cyclic adenosine monophosphate. Also, the paper reviews what these advances mean to patients and clinicians and elaborates on how these changes can be immediately applied to clinical practice. There is an urgent need for discovery of new therapies targeted toward ADPKD in comparison with therapeutic progress of all other renal diseases.
authors.affiliation: Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO, USA. imedhelal@voila.fr
authors.forename: Imed
authors.initials: I
authors.lastname: Helal
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D018450:Disease Progression; D020536:Enzyme Activators / Q000627:therapeutic use; D005440:Fluid Therapy; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D016891:Polycystic Kidney, Autosomal Dominant / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D012084:Renin-Angiotensin System / Q000187:drug effects; D040242:Risk Reduction Behavior; D016896:Treatment Outcome; D014667:Vasopressins / Q000037:antagonists & inhibitors
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D020536:Enzyme Activators; D006727:Hormone Antagonists; D014667:Vasopressins; D055372:AMP-Activated Protein Kinases